Kala Bio Inc (NAS:KALA)
$ 6.72 -0.1375 (-2.01%) Market Cap: 30.98 Mil Enterprise Value: 19.45 Mil PE Ratio: 0 PB Ratio: 4.51 GF Score: 46/100

Q2 2022 Kala Pharmaceuticals Inc Earnings Call Transcript

Aug 11, 2022 / 12:00PM GMT
Release Date Price: $16.4 (-5.75%)
Operator

Good day. My name is Shantel, and I will be your conference operator today. At this time, I would like to welcome everyone to the Kala Pharmaceuticals Second Quarter 2022 Financial Results Conference Call. As a reminder, today's conference call is being recorded. (Operator Instructions). Hannah Deresiewicz from Stern Investor Relations. You may begin your conference.

Hannah Deresiewicz
Stern Investor Relations, Inc. - Senior Associate

Thank you, operator, and thank you all for participating in today's call. Joining me from the company are Mark Iwicki, Chairman and Chief Executive Officer; Kim Brazzell, Head of R&D and Chief Medical Officer; and Mary Reumuth, Chief Financial Officer. Darius Kharabi, our Chief Business Officer, will also be joining us for the Q&A portion of today's call.

During this call, we will be referring to non-GAAP financial measures, which are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot